FDA Approves Polatuzumab Vedotin Plus R-CHP for Previously Untreated DLBCL

The FDA has approved polatuzumab vedotin-piiq (Polivy) plus rituximab (Rituxan), cyclophosphamide, doxorubicin, and prednisone for use in adult patients who have previously untreated diffuse large B-cell lymphoma, not otherwise specified or high-grade B-cell lymphoma and who have an International Prognostic Index score of two or greater.

FDA

FDA

The FDA has approved polatuzumab vedotin-piiq (Polivy) plus rituximab (Rituxan), cyclophosphamide, doxorubicin, and prednisone (R-CHP) for use in adult patients who have previously untreated diffuse large B-cell lymphoma (DLBCL), not otherwise specified (NOS) or high-grade B-cell lymphoma (HGBL) and who have an International Prognostic Index score of two or greater.1

The regulatory decision converts the June 2019 accelerated approval of the antibody-drug conjugate (ADC) in combination with bendamustine and rituximab (BR) for the treatment of patients with relapsed or refractory DLBCL who have previously received at least 2 therapies into a regular one.2 This approval was based on data from the phase 1b/2 GO29365 trial (NCT02257567), in which 40% of patients receiving the polatuzumab vedotin regimen achieved complete response (CR) compared with 18% of patients in the BR-alone arm, meeting the primary end point of the study.

The frontline approval is supported by findings from the phase 3 POLARIX trial (NCT03274492), in which polatuzumab vedotin plus R-CHP (n = 440) significantly improved progression-free survival (PFS) compared with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP; n = 439) in this patient population.3

The addition of the ADC to R-CHP resulted in a 27% reduction in the risk of disease progression, relapse or death vs R-CHOP (HR, 0.73; 95% CI, 0.57-0.95; P < .02). Data presented at the 2022 Pan Pacific Lymphoma Conference showed that the 2-year PFS rate in the investigative arm was 76.7% (95% CI, 72.7%-80.8%) vs 70.2% in the control arm (95% CI, 65.8%-74.6%).

“It has been nearly 20 years since a new treatment option has become available to people newly diagnosed with diffuse large B-cell lymphoma,” Levi Garraway, MD, PhD, chief medical officer and head of global product development at Roche, stated in a news release. “Today’s decision from the FDA to approve Polivy in combination with R-CHP in this setting brings a much-needed new treatment option which may improve outcomes and bring other benefits to many patients with this aggressive lymphoma.”

The international, randomized, double-blind, placebo-controlled POLARIX enrolled patients with previously untreated LBCL, an International Prognostic Index score between 2 and 5 representing low-intermediate to high-risk disease, no central nervous system disease, and no primary mediastinal large B-cell lymphoma.4

The trial included patients with several types of LBCL, including DLBCL NOS, HBCL with MYC and BCL2 and/or BCL6 rearrangements, HGBL NOS, and other low-grade B-cell lymphomas, including T-cell/histiocyte-rich LBCL, Epstein–Barr virus–positive DLBCL, ALK-positive LBCL, and HHV8-positive DLBCL.

Participants were randomly assigned 1:1 to 1.8 mg/kg of polatuzumab vedotin once daily plus 375 mg/m2 of rituximab, 750 mg/m2 of cyclophosphamide, and 50 mg/m2 of doxorubicin for six 21-day cycles or standard-of-care R-CHOP. All patients received 375 mg/m2 of rituximab daily for cycles 7 and 8.

Investigator-assessed PFS served as the trial's primary end point. Key secondary end points comprised event-free survival (EFS), end-of-treatment PET-CT CR rate, disease-free survival (DFS), overall survival (OS), and safety.

Additional data showed that the hazard ratio for EFS with polatuzumab vedotin plus R-CHP vs R-CHOP was 0.75 (95% CI, 0.58-0.96; P = .02). No significant difference between PET-CR rate at end of treatment was observed (78.0% vs 74.0%; P =.16), although DFS data suggested that responses are more durable with the polatuzumab vedotin combination (HR, 0.70; 95% CI, 0.50-0.98).

No significant difference in OS was observed between the treatment arms (HR, 0.94; 95% CI, 0.65-1.37; P = 0.75). At a median follow-up of 39.7 months, the median OS was not reached in either arm. At 2 years, the OS rate was 88.7% in both arms.

The toxicity profile of polatuzumab vedotin plus R-CHP proved to be comparable to that of R-CHOP.1 Grade 3 or 4 adverse effects (AEs) were experienced by 57.7% of those on the investigative arm and 57.5% of those on the control arm; serious AEs occurred in 34.0% and 30.6% of patients, respectively. Mroeover, grade 5 toxicities were reported in 3.0% of those in the ADC arm vs 2.3% of those in the placebo arm. Toxicities resulted in dose reductions for 9.2% of those who received polatuzumab vedotin and 13.0% of those who did not.

The most commonly reported toxicities included peripheral neuropathy, nausea, fatigue, diarrhoea, constipation, alopecia, and mucositis. Lymphopenia and neutropenia were the most commonly experienced grade 3 or 4 AEs.

The frontline regulatory approval follows the FDA's Oncologic Drugs Advisory Committee vote of 11 to 2 in March 2023 that data from POLARIX support a favorable benefit-risk profile for polatuzumab vedotin in this population.5

References

  1. [Ad hoc announcement pursuant to Art. 53 LR] FDA approves Roche’s Polivy in combination with R-CHP for people with certain types of previously untreated diffuse large B-cell lymphoma. News release. Roche. April 19, 2023. Accessed April 19, 2023. https://www.roche.com/media/releases/med-cor-2023-04-19
  2. FDA approves polatuzumab vedotin-piiq for diffuse large B-cell lymphoma. FDA. June 10, 2019. Accessed April 19, 2023. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-polatuzumab-vedotin-piiq-diffuse-large-b-cell-lymphoma
  3. Mehta-Shah N, Tilly H, Morschhauser F, et al. Polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP) versus rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) therapy in patients with previously untreated diffuse large B-cell lymphoma (DLBCL): results from the phase III POLARIX study. Presented at: 2022 Pan Pacific Lymphoma Conference; July 18-22, 2022; Koloa, HI. https://f5cb18b31bcff05c4c68-a0ad32938c5dd185096ff3214cd552d4.ssl.cf1.rackcdn.com/2089833-1655492027.pdf
  4. A study comparing the efficacy and safety of polatuzumab vedotin with rituximab-cyclophosphamide, doxorubicin, and prednisone (R-CHP) versus rituximab-cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in participants with diffuse large B-cell lymphoma (POLARIX). ClinicalTrials.gov. Updated May 31, 2022. Accessed April 19, 2023. https://clinicaltrials.gov/ct2/show/NCT03274492
  5. Meeting of the Oncologic Drugs Advisory Committee (ODAC). Youtube. March 9, 2023. Accessed April 19, 2023. https://www.youtube.com/watch?v=zCf87ABhqpU
Related Videos
Eunice Wang, MD
Veronika Bachanova, MD, PhD
Eunice Wang, MD
Craig Sauter, MD
Akash Mukherjee, MD, hematologist, oncologist, University of Arkansas for Medical Sciences, (UAMS), assistant professor, Division of Hematology/Oncology, the Winthrop Cancer Institute, the UAMS College of Medicine,
Yuliya Linhares, MD, medical oncologist, chief of Lymphoma Services, Miami Cancer Institute
Ariel Perez Perez, MD, hematologist, medical oncologist, Miami Cancer Institute
Related Content